Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer’s disease management

References

• Abo El-Khair D, El-Safti F, Nooh H, El-Mehi A. (2014). A comparative study on the effect of high cholesterol diet on the hippocampal CA1 area of adult and aged rats. Anat Cell Biol 47:117–26
   PubMedGoogle Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. (2013). Liposome: classification, preparation, and applications. Nanoscale Res Lett 8:102–10
   PubMed Web of Science ®Google Scholar
• Alam S, Khan ZI, Mustafa G, et al. (2012). Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomedicine 7:5705–18
   PubMed Web of Science ®Google Scholar
• Baldrick P. (2010). The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 56:290–9
   PubMed Web of Science ®Google Scholar
• Bamrungsap S, Zhao Z, Chen T, et al. (2012). Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine 7:1253–71
   PubMed Web of Science ®Google Scholar
• Bethesda M. (1985). Committee on care and use of laboratory animals. Guide for the care and use of laboratory animals. Institute of Laboratory Animals. Resources commission on life sciences. Revised edition. NIH Publication NO. 86-23. Bethesda (MD): National Institute of Health
   Google Scholar
• Bhatt R, Singh D, Prakash A, Mishra N. (2015). Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. disease. Drug Deliv 22:931–9
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Haertel C, Maelicke A, Montag D. (2014). Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease. PloS One 9:e89454
   PubMed Web of Science ®Google Scholar
• Botner S, Friedman A, Sintov A. (2012). Direct Delivery of intranasal insulin to the brain via microemulsion as a putative treatment of CNS functioning disorders. J Nanomed Nanotechol 3:136
   Google Scholar
• Carmo Carreiras M, Mendes E, Jesus Perry M, et al. (2013). The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr Top Med Chem 13:1745–70
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu L. (2012). Modern methods for delivery of drugs across the blood-brain barrier. – barrier. Adv Drug Deliv Rev 64:640–65
   PubMed Web of Science ®Google Scholar
• Contestabile A. (2011). The history of the cholinergic hypothesis. Behav Brain Res 221:334–40
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Hellström-Lindahl E, Flores-Flores C, et al. (2004). Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J Neurochem 88:1102–13
   PubMed Web of Science ®Google Scholar
• Darreh-Shori T, Kadir A, Almkvist O, et al. (2008). Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging 29:168–84
   PubMed Web of Science ®Google Scholar
• Davidsson P, Blennow K, Andreasen N, et al. (2001). Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 300:157–60
   PubMed Web of Science ®Google Scholar
• Di Cara B, Panayi F, Gobert A, et al. (2007). Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. Int J Neuropsychopharmacol 10:383–99
   PubMed Web of Science ®Google Scholar
• Dineley KT, Pandya AA, Yakel JL. (2015). Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci 36:96–108
   PubMed Web of Science ®Google Scholar
• Elgadir MA, Uddin MS, Ferdosh S, et al. (2014). Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: a review. J Food Drug Anal 23:619–29
   PubMed Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, Featherstone RM. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95
   PubMed Web of Science ®Google Scholar
• Elnaggar YS, Etman SM, Abdelmonsif DA, Abdallah OY. (2015). intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci 104:3544–56
   PubMed Web of Science ®Google Scholar
• Feldman AT, Wolfe D. (2014). Tissue processing and hematoxylin and eosin staining. Methods Mol Biol 1180:31–43
   PubMedGoogle Scholar
• Gage GJ, Kipke DR, Shain W. (2012). Whole animal perfusion fixation for rodents. J Vis Exp 65:35–64
   Google Scholar
• Galgatte UC, Kumbhar AB, Chaudhari PD. (2014). Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Drug Deliv 21:62–73
   PubMed Web of Science ®Google Scholar
• Geerts H, Guillaumat P-O, Grantham C, et al. (2005). Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 1033:186–93
   PubMed Web of Science ®Google Scholar
• Goh CW, Aw CC, Lee JH, et al. (2011). Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats. Drug Metab Dispos 39:402–11
   PubMed Web of Science ®Google Scholar
• Hager K, Baseman AS, Nye JS, et al. (2014). Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. disease. Neuropsychiatr Dis Treat 10:391–401
   PubMed Web of Science ®Google Scholar
• Hanafy A, Farid R, El Gamal S. (2015). Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for alzheimer's disease management: preparation and detection in rat brain. Drug Dev Ind Pharm 41:2055–68
   PubMed Web of Science ®Google Scholar
• Haque S, Md S, Fazil M, et al. (2012). Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. for targetingPharmacokinetic and evaluation. Carbohydr Polym 89:72–9
   PubMed Web of Science ®Google Scholar
• Harkema JR, Carey SA, Wagner JG. (2006). The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol 34:252–69
   PubMed Web of Science ®Google Scholar
• Hu L, Sun Y, Wu Y. (2013). Advances in chitosan-based drug delivery vehicles. Nanoscale 5:3103–11
   PubMed Web of Science ®Google Scholar
• Illum L, Farraj NF, Davis SS. (1994). Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 11:1186–9
   PubMed Web of Science ®Google Scholar
• Irie T, Uekama K. (1997). Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 86:147–62
   PubMed Web of Science ®Google Scholar
• Jain A, Gulbake A, Shilpi S, et al. (2013). A new horizon in modifications of chitosan: syntheses and applications. Crit Rev Ther Drug Carrier Syst 30:91–181
   PubMed Web of Science ®Google Scholar
• Kreuter J. (2014). Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev 71:2–14
   PubMed Web of Science ®Google Scholar
• Leonard AK, Sileno AP, Brandt GC, et al. (2007). In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm 335:138–46
   PubMed Web of Science ®Google Scholar
• Li W, Zhou Y, Zhao N, et al. (2012). Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol 34:272–9
   PubMed Web of Science ®Google Scholar
• Lilienfeld S. (2002). Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev 8:159–76
   PubMedGoogle Scholar
• Liu H-L, Yang H-L, Lin B-C, et al. (2015). Toxic effect comparison of three typical sterilization nanoparticles on oxidative stress and immune inflammation response in rats. Toxicol Res 4:486–93
   Web of Science ®Google Scholar
• Lochhead JJ, Thorne RG. (2012). Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64:614–28
   PubMed Web of Science ®Google Scholar
• Mannens G, Snel C, Hendrickx J, et al. (2002). The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 30:553–63
   PubMed Web of Science ®Google Scholar
• Md S, Khan RA, Mustafa G, et al. (2013). Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 48:393–405
   PubMed Web of Science ®Google Scholar
• Md S, Mustafa G, Baboota S, Ali J. (2015). Nanoneurotherapeutics approach intended for direct nose to brain delivery. Drug Dev Ind Pharm 41:1922–34
   PubMed Web of Science ®Google Scholar
• Migliore MM, Vyas TK, Campbell RB, et al. (2010). Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci 99:1745–61
   PubMed Web of Science ®Google Scholar
• Moffat AC, Osselton MD, Widdop B. (2011). Clarke's analysis of drugs and poisons. London: Pharmaceutical Press
   Google Scholar
• Nordberg A, Darreh-Shori T, Peskind E, et al. (2009). Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 6:4–14
   PubMed Web of Science ®Google Scholar
• Ong W-Y, Shalini S-M, Costantino L. (2014). Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. Curr Med Chem 21:4247–56
   PubMed Web of Science ®Google Scholar
• Ozer J, Ratner M, Shaw M, et al. (2008). The current state of serum biomarkers of hepatotoxicity. Toxicology 245:194–205
   PubMed Web of Science ®Google Scholar
• Priprem A, Chonpathompikunlert P, Sutthiparinyanont S, Wattanathorn J. (2011). Antidepressant and cognitive activities of intranasal piperine-encapsulated liposomes. Adv Biosci Biotechnol 2:108–16
   Google Scholar
• Ravi P, Aditya N, Patil S, Cherian L. (2015). Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv 22:903–10
   PubMed Web of Science ®Google Scholar
• Salama EEA, Ali AHA, Aldahmash AM, et al. (2013). The role of vitamin e in cerebral hypoxia: an ultrastructural study. Surg Sci 4:100–6
   Google Scholar
• Sapan CV, Lundblad RL. (2015). Review of methods for determination of total protein and peptide concentration in biological samples. Proteomics Clin Appl 9:268–76
   PubMed Web of Science ®Google Scholar
• Tumiatti V, Milelli A, Minarini A, et al. (2008). Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. J Med Chem 51:7308–12
   PubMed Web of Science ®Google Scholar
• Wu H, Li J, Zhang Q, et al. (2012). A novel small Odorranalectin-bearing cubosomes: Preparation, brain delivery and pharmacodynamic study on amyloid treated rats following intranasal administration. Eur J Pharm Biopharm 80:368–78
   PubMed Web of Science ®Google Scholar
• Xu J, Shi H, Ruth M, et al. (2013). Acute toxicity of intravenously administered titanium dioxide nanoparticles in mice. PloS One 8:e70618
   PubMed Web of Science ®Google Scholar
• Yano K, Koda K, Ago Y, et al. (2009). Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice. Br J Pharmacol 156:173–80
   PubMed Web of Science ®Google Scholar
• Yun JW, Yoon JH, Kang BC, et al. (2015). The toxicity and distribution of iron oxide-zinc oxide core-shell nanoparticles in C57BL/6 mice after repeated subcutaneous administration. J Appl Toxicol 35:593–602
   PubMed Web of Science ®Google Scholar
• Zensi A, Begley D, Pontikis C, et al. (2009). Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 137:78–86
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiong H. 2014. Brain tissue preparation, sectioning, and staining. In: Xiong H, Gendelman H, eds. Current laboratory methods in neuroscience research. New York: Springer, 3–30
   Google Scholar
• Zhang X-D, Wu D, Shen X, et al. (2011). Size-dependent in vivo toxicity of PEG-coated gold nanoparticles. Int J Nanomedicine 6:2071–81
   PubMed Web of Science ®Google Scholar